-+ 0.00%
-+ 0.00%
-+ 0.00%

BMO Capital Initiates Coverage On Axsome Therapeutics with Outperform Rating, Announces Price Target of $310

Benzinga·07/21/2026 09:48:01
语音播报
BMO Capital analyst Malcolm Hoffman initiates coverage on Axsome Therapeutics (NASDAQ:AXSM) with a Outperform rating and announces Price Target of $310.